Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14825513 | 0.97 | OPRD1 (0.48) | CYP1A2HSD17B10OPRD1LMNAMAPT | |
| SCHEMBL14825668 | 0.92 | OPRD1 (0.48) | CYP1A2OPRD1LMNAMAPTKCNH2 | |
| SCHEMBL14825614 | 0.89 | ATM (0.53) | CYP1A2OPRD1LMNAMAPTKCNH2 | |
| SCHEMBL14825540 | 0.88 | OPRD1 (0.48) | CYP1A2OPRD1LMNAKCNH2OPRM1 | |
| SCHEMBL14825469 | 0.86 | CACNA2D1 (0.53) | CYP1A2OPRD1LMNAKCNH2OPRM1 | |
| SCHEMBL14825483 | 0.86 | ATM (0.49) | CYP1A2OPRD1LMNAMAPTKCNH2 | |
| SCHEMBL14825846 | 0.85 | OPRD1 (0.51) | CYP1A2OPRD1LMNAMAPTKCNH2 | |
| SCHEMBL14825527 | 0.84 | ATM (0.47) | CYP1A2OPRD1LMNAMAPTKCNH2 | |
| SCHEMBL14825512 | 0.84 | ATM (0.53) | CYP1A2OPRD1KCNH2OPRM1MEN1 | |
| SCHEMBL14825497 | 0.83 | CYP1A2 (0.45) | CYP1A2OPRD1LMNAMAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | CYP1A2 494/4885HSD17B10 2281/4885OPRD1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.